MedTrace Logo

Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD

NCT03131050 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2018-12-26

No results posted yet for this study

Summary

Despite the availability of a wide range of antidepressant drugs, clinical trials indicate that 30% to 40% of patients with major depression fail to respond to first-line antidepressant treatment, despite adequate dosage, duration, and compliance. Moreover, in those patients who do experience symptomatic relief following conventional anti-depressant treatment, clinical improvement is not evident for 3-4 weeks. Thus, there is a clear need to develop novel and improved therapeutics for unipolar depression.

A previous study showed that the intravenous administration of scopolamine produces antidepressant effects. This study is designed to determine if scopolamine combine with Escitalopram produce antidepressant effects at an early stage.

Conditions

Interventions

DRUG

Scopolamine

Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;

DRUG

Escitalopram

Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment

DRUG

Saline

Intramuscular injection with saline (1ml, QD or Bid) during the first three days;

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Gang Wang, M.D.,Ph.D. · Beijing Anding Hospital, Capital Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-15
Primary Completion
2018-02-08
Completion
2018-03-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03131050 on ClinicalTrials.gov